Update: Fingers in the field
Omega is making steady progress with Visitect, an HIV monitoring point-of care (PoC) diagnostic, after initial field trials in India and Kenya. Further optimisation of Visitect is needed for the finger-stick blood samples. We have reduced our expectations for FY15 sales to £0.5m as the timetable for further optimisation and the next larger, 1,000-patient field studies have to be clarified. Allergy iSYS development is progressing to a 40-test launch menu, 24 tests are validated with eight of these transferred to manufacturing. Normalised FY14 PBT was £1.1m on revenue of £11.6m.Omega Diagnostics Group is a holding company. Through its subsidiaries, Co. is engaged in the manufacturing, development and distribution of medical diagnostics products. Co. has three operating divisions: Allergy and autoimmune, which in the research, development, production and marketing of in-vitro allergy and autoimmune tests; Food intolerance, which provides clinical analysis to the general public, clinics and health professionals as well as supplying the consumer; and Infectious disease and Other, which comprise of research, development, production and marketing of kits to aid the diagnosis of infectious diseases.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.